JP6431083B2 - Ｆｇｆ−１８化合物の投与計画 - Google Patents

Ｆｇｆ−１８化合物の投与計画 Download PDF

Info

Publication number
JP6431083B2
JP6431083B2 JP2016553329A JP2016553329A JP6431083B2 JP 6431083 B2 JP6431083 B2 JP 6431083B2 JP 2016553329 A JP2016553329 A JP 2016553329A JP 2016553329 A JP2016553329 A JP 2016553329A JP 6431083 B2 JP6431083 B2 JP 6431083B2
Authority
JP
Japan
Prior art keywords
fgf
cartilage
pharmaceutical composition
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016553329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512194A (ja
JP2017512194A5 (cg-RX-API-DMAC7.html
Inventor
ハー．ラーデル クリストフ
ハー．ラーデル クリストフ
ゲーリング ハンス
ゲーリング ハンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2017512194A publication Critical patent/JP2017512194A/ja
Publication of JP2017512194A5 publication Critical patent/JP2017512194A5/ja
Application granted granted Critical
Publication of JP6431083B2 publication Critical patent/JP6431083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016553329A 2014-02-20 2015-02-20 Ｆｇｆ−１８化合物の投与計画 Active JP6431083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017512194A JP2017512194A (ja) 2017-05-18
JP2017512194A5 JP2017512194A5 (cg-RX-API-DMAC7.html) 2018-03-08
JP6431083B2 true JP6431083B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Ｆｇｆ−１８化合物の投与計画
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Ｆｇｆ−１８化合物の投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Ｆｇｆ−１８化合物の投与計画

Country Status (25)

Country Link
US (2) US9724388B2 (cg-RX-API-DMAC7.html)
EP (2) EP3119417B1 (cg-RX-API-DMAC7.html)
JP (2) JP6431083B2 (cg-RX-API-DMAC7.html)
KR (2) KR102410988B1 (cg-RX-API-DMAC7.html)
CN (2) CN106232622A (cg-RX-API-DMAC7.html)
AR (2) AR099558A1 (cg-RX-API-DMAC7.html)
AU (2) AU2015220777B2 (cg-RX-API-DMAC7.html)
BR (2) BR112016018685A2 (cg-RX-API-DMAC7.html)
CA (2) CA2938793A1 (cg-RX-API-DMAC7.html)
DK (2) DK3107559T3 (cg-RX-API-DMAC7.html)
ES (2) ES2688551T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20181572T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040350T2 (cg-RX-API-DMAC7.html)
IL (2) IL247083B (cg-RX-API-DMAC7.html)
LT (2) LT3119417T (cg-RX-API-DMAC7.html)
MX (2) MX2016010872A (cg-RX-API-DMAC7.html)
NZ (2) NZ723148A (cg-RX-API-DMAC7.html)
PL (2) PL3119417T3 (cg-RX-API-DMAC7.html)
PT (2) PT3119417T (cg-RX-API-DMAC7.html)
RS (2) RS57853B1 (cg-RX-API-DMAC7.html)
RU (2) RU2700582C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201606502YA (cg-RX-API-DMAC7.html)
SI (2) SI3119417T1 (cg-RX-API-DMAC7.html)
WO (2) WO2015124731A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201605547B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3107592T (pt) 2014-02-20 2018-12-03 Merck Patent Gmbh Implante que compreende fgf-18
HRP20181572T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
EP3250925B1 (en) 2015-01-29 2019-04-10 Ares Trading S.A. Immunoassays for highly positively charged proteins
KR20180115270A (ko) 2016-02-22 2018-10-22 노파르티스 아게 Fxr 효능제를 사용하는 방법
HRP20220737T1 (hr) 2017-09-29 2022-09-02 Merck Patent Gmbh Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18
US11513128B2 (en) 2017-09-29 2022-11-29 Merck Patent Gmbh Metabolic biomarkers for predicting responsiveness to FGF-18 compound
HRP20240665T1 (hr) 2018-09-10 2024-08-16 Merck Patent Gmbh Markeri korisni u strategijama obogaćivanja za liječenje osteoartritisa
EP3920959A1 (en) * 2019-02-08 2021-12-15 Merck Patent GmbH Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500742C (en) * 2002-10-07 2014-02-18 Zymogenetics, Inc. Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
WO2007070983A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
BRPI0715728A8 (pt) * 2006-08-25 2018-04-03 Ares Trading Sa tratamento de distúrbios cartilaginosos
EA015644B1 (ru) * 2006-08-25 2011-10-31 Арес Трейдинг С.А. Способ лечения заболеваний хряща
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
JP6277121B2 (ja) * 2011-03-22 2018-02-07 アドヴィナス・セラピューティックス・リミテッド 置換された縮合三環式化合物、その組成物および医学的応用
PT3107592T (pt) 2014-02-20 2018-12-03 Merck Patent Gmbh Implante que compreende fgf-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 ｆｇｆ－１８
HRP20181572T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18

Also Published As

Publication number Publication date
AR099510A1 (es) 2016-07-27
BR112016018696A2 (pt) 2017-10-17
KR20160116000A (ko) 2016-10-06
RU2691946C2 (ru) 2019-06-19
DK3107559T3 (en) 2018-10-15
KR102410986B1 (ko) 2022-06-17
WO2015124731A1 (en) 2015-08-27
RU2016137292A (ru) 2018-03-21
US9724388B2 (en) 2017-08-08
LT3119417T (lt) 2018-10-25
EP3119417A1 (en) 2017-01-25
LT3107559T (lt) 2018-10-25
SI3119417T1 (sl) 2018-11-30
IL247084B (en) 2019-09-26
RU2700582C2 (ru) 2019-09-18
DK3119417T3 (en) 2018-10-22
WO2015124727A1 (en) 2015-08-27
KR20160116001A (ko) 2016-10-06
RU2016137292A3 (cg-RX-API-DMAC7.html) 2018-09-17
CA2938793A1 (en) 2015-08-27
IL247083A0 (en) 2016-09-29
JP6431082B2 (ja) 2018-11-28
ES2688551T3 (es) 2018-11-05
AU2015220773B2 (en) 2020-10-08
AU2015220777A1 (en) 2016-09-01
IL247083B (en) 2019-09-26
PT3107559T (pt) 2018-10-31
AU2015220777B2 (en) 2020-10-22
PL3107559T3 (pl) 2019-01-31
CN106232622A (zh) 2016-12-14
US20170072017A1 (en) 2017-03-16
AU2015220773A1 (en) 2016-09-01
JP2017512194A (ja) 2017-05-18
SI3107559T1 (sl) 2018-11-30
PL3119417T3 (pl) 2019-01-31
EP3107559A1 (en) 2016-12-28
AR099558A1 (es) 2016-08-03
IL247084A0 (en) 2016-09-29
RS57709B1 (sr) 2018-12-31
US9889179B2 (en) 2018-02-13
NZ723139A (en) 2022-12-23
BR112016018685A2 (pt) 2017-10-17
CN106456713A (zh) 2017-02-22
RU2016137289A3 (cg-RX-API-DMAC7.html) 2018-10-19
MX2016010871A (es) 2016-11-17
JP2017507142A (ja) 2017-03-16
RU2016137289A (ru) 2018-03-21
EP3107559B1 (en) 2018-07-11
RS57853B1 (sr) 2018-12-31
CA2938791A1 (en) 2015-08-27
NZ723148A (en) 2022-08-26
ZA201605547B (en) 2019-09-25
PT3119417T (pt) 2018-10-31
EP3119417B1 (en) 2018-07-11
ZA201605548B (en) 2018-12-19
HUE040350T2 (hu) 2019-03-28
SG11201606505UA (en) 2016-09-29
KR102410988B1 (ko) 2022-06-17
MX2016010872A (es) 2016-11-17
SG11201606502YA (en) 2016-09-29
HRP20181572T1 (hr) 2018-11-30
US20170056474A1 (en) 2017-03-02
HRP20181570T1 (hr) 2018-11-30
ES2689071T3 (es) 2018-11-08

Similar Documents

Publication Publication Date Title
JP6431083B2 (ja) Ｆｇｆ−１８化合物の投与計画
KR101419961B1 (ko) Ｆｇｆ-18 로 연골 질환의 치료
CN101505787B (zh) 软骨障碍的治疗
RU2745453C2 (ru) Комбинированная композиция, содержащая соединение fgf-18
HK1231895A1 (en) Fgf-18 compound dosing regimen
HK1231754A1 (zh) Fgf-18化合物给药方案
HK1129852A (en) Treatment of cartilage disorders
HK1129852B (en) Treatment of cartilage disorders
HK1173392A (en) Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181101

R150 Certificate of patent or registration of utility model

Ref document number: 6431083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250